Document is current
Any future updates will be listed below
-
Authors
Carli, Vladimir
Wasserman, Danuta
Hadlaczky, Gergö
Petros, Nuhamin Gebrewold
Carletto, Sara
Citi, Luca
Dinis, Sergio
Gentili, Claudio
Gonzalez-Martinez, Sergio
Aldo De Leonibus,
Meyer, Björn
Ostacoli, Luca
Ottaviano, Manuel
Ouakinin, Silvia
Paradiso, Rita
Poli, Riccardo
Rocha, Isabel
Settanta, Carmen
Waldmeyer, Maria Teresa Arredondo
Valenza, Gaetano
Scilingo, Enzo Pasquale
-
Funding
Funding for this research was provided by:
Horizon 2020 (689691)
- License Information
-
More Information
Article History
Received: 3 October 2018
Accepted: 11 February 2020
First Online: 2 March 2020
Ethics approval and consent to participate
: The study received ethical approval by the European Commission as a prerequisite of funding approval for the project. Ethical approval for the NEVERMIND study was submitted and approved by the following local research ethics committee in each of the countries where the intervention is implemented: Any important protocol modifications and amendments will be immediately communicated to all the participating centres as well as the European Commission. Researchers obtain a written informed consent from each subject after explaining all aspects of the study that is relevant for the participant to make his or her decision.
: Not applicable.
: BM declares that he is employed by Gaia AG, the developer and owner of Deprexis, an internet-based intervention for depression, which is offered selectively to patients within the context of the NEVERMIND system. Other authors declare that they have no competing interests.
